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using the NanoString platform. Patients were classified into low- 
versus high-risk groups based on pathological stage (≤ T2 versus 
≥ T3), Gleason Score (GS) (≤ 7 versus ≥ 8), post-operative PSA 
level (≤0.2 versus > 0.2), margin status (positive versus negative) 
and nodal status (positive versus negative). 
Results: Seventy patients were recruited prospectively from 
2015 to 2016 (median age = 64.5 years; range 48-77), and 30 
patients were used as a discovery cohort. Five hundred and 
eighty-eight miRNAs were differentially expressed in serum 
exosomes (301 overexpressed and 287 underexpressed). Of 
these, three miRNAs (miR-122, miR-4421, and miR-92a) and 2 
miRNAs (miR-145 and miR-630) were significantly overexpressed 
and underexpressed (> 2 fold difference, p < 0.05) in patients 
with high pathological stage and GS, respectively. miR-630 was 
found to be the only miRNA significantly downregulated in 
patients harboring all three high-risk features of GS, pathological 
stage and post-operative PSA. Pathway analysis was performed 
and indicated that these differentially expressed miRNAs were 
highly related to PCa carcinogenesis, progression, and 
angiogenesis. Preclinical studies were carried out to investigate 
the biological role of selected miRNAs in PCa proliferation, 
invasion and response to radiation and chemotherapy. 
Conclusions: This is the first report to our knowledge, detailing 
the discovery of a unique signature of exosomal miRNA obtained 
from PCa patient sera post-RP, with direct comparison to 
clinicopathological factors. This exosomal miRNA signature will 
be assessed in a validation cohort to assess its predictive value 
for biochemical recurrence post-RP. 
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Purpose: Radiation necrosis occurs in 10-20% of patients who 
undergo stereotactic radiosurgery (SRS) for brain metastases. 
There are currently no established methods for differentiating 
tumour progression from radionecrosis, and the temporal 
evolution and pathophysiology of vascular changes after high 
dose radiation is poorly understood. Intravoxel incoherent 
motion (IVIM) is a method using MRI-based diffusion-weighted 
imaging (DWI) to assess regional perfusion without intravenous 
contrast. IVIM may help in monitoring the evolution of vascular 
damage and its relationship to tumour control, progression and 
radionecrosis. This study evaluates the temporal evolution of 
IVIM perfusion fraction in brain metastases treated with SRS. 
Methods and Materials: Seventeen patients with brain 
metastases were prospectively enrolled in an REB-approved 
study and underwent MRI scans (including DWI with six b-values) 
at baseline, one week, and one month post-SRS, and were 
subsequently followed with MRI surveillance scans every three 
months. The perfusion fraction (f) was calculated using linear 
fitting. A region of interest was defined by contouring the 
metastases on the post-gadolinium T1-weighted images. The 
mean f and apparent diffusion coefficient (ADC) were calculated 
for each metastasis. Hemorrhagic metastases were excluded due 
to artifacts in associated DWI voxels. 
Results: The primary site of disease was lung (n = 7), breast (n = 
6), rectal (n = 2) and melanoma (n = 2, excluded due to 
hemorrhage). Four patients were lost to follow up. A total of nine 
patients with 10 metastases were included in the final analysis 
with a median follow up of six months. Of the 10 brain 
metastases analyzed, seven exhibited regression with an average 
volume decrease of 81%. The three remaining lesions showed 
early regression followed by progressive enhancement on T1-
weighted images deemed to be consistent with radionecrosis, 
with an average volume increase of 68%. For the lesions that 
responded to SRS, the baseline perfusion fraction (average = 
9.2%) increased slightly at one week post-SRS (average = 9.7%) 
and slightly further at one month (average = 10.9%). For the 
lesions that later developed necrosis, the baseline f (average = 
9.2%) decreased at one week (average = 7.3%) then rebounded 
back to near baseline at one month (average = 8.8%). There was 
a statistically significant difference in the change in f from 
baseline to one week between two groups (average change for 
responders = +6.4%, for necrosis = -19.4%, p = 0.047). There were 
no trends in differences in ADC between the two groups at any 
time point. 
Conclusions: IVIM perfusion fraction may identify brain 
metastases that go on to develop radionecrosis after SRS. An 
early decrease in f could signify a higher degree of SRS-induced 
vascular damage leading to late necrosis. A retrospective 
analysis of an additional 60 patients is currently underway to 
further evaluate the utility of IVIM perfusion fraction. 
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Purpose: The purpose of this study was to evaluate clinical and 
pathologic factors associated with survival in patients with oral 
cavity squamous cell carcinoma (OCSCC), and to compare the 
prognostic performance of clinicopathological models against 
the routinely used TNM staging. 
Methods and Materials: All patients diagnosed with OCSCC 
between 2001-2009 and treated with surgical resection at a 
tertiary referral head and neck surgery department within a 
university centre in Brazil, were identified. Data were 
prospectively collected from hospital charts, tumour registry 
files, and patient interviews. The impact of clinical and 
pathologic risk factors on overall survival (OS) of patients with 
OCSCC was evaluated using the Kaplan-Meier method and log-
rank tests. Factors associated with OS were investigated with 
multivariable Cox models. Results were considered statistically 
significant at p-value < 0.05. Model fit was evaluated using the 
Akaike Information Criterion (AIC). 
Results: A total of 243 patients with OCSCC were identified, 
including 26.8% women and 73.2% men, with a mean age at 
diagnosis of 60.4 (standard error 12.2) years. TNM Stages I, II, 
and III disease comprised 17%, 13%, and 13% of cases 
respectively. Stage IV disease comprised 56% of cases. Median 
follow- up was 28.7 months (interquartile range 11.8–60.0), and 
41.6% died during follow up. Individual factors predictive of all-
cause mortality on univariate analysis included age, TNM Stage, 
pathologic T Stage, pathologic N Stage, tumour size, depth of 
invasion, extracapsular extension, perineural invasion, number 
of symptoms (pain, globus sensation, dysphagia, odynophagia, 
bleeding, otalgia, airway obstruction necessitating 
tracheostomy), and weight loss percentage (p < 0.05). Sex, 
education, tumour differentiation, surgical margin status, 
smoking status, cumulative pack-year smoking history, alcohol 
consumption status, and daily alcohol consumption in grams 
were not correlated with survival. On multivariate analyses, size 
of tumour in centimeters [HR 1.27(1.15 - 1.41)] and age [HR 
1.05(1.03 -1.08)] remained as independent poor prognostic 
factors. There was a trend towards poor prognosis for pathologic 
N Stage [HR 1.29(0.97-1.72)]; margin positivity [HR 1.06(0.56 - 
1.98)]; extracapsular extension [HR 1.41(0.74 - 2.71)]; each 
additional associated symptom [HR 1.12(0.95 - 1.32)]; and per 
pack year increase in tobacco consumption [HR 1.01(1.00 - 
1.01)]. Clinicopathological models based on combinations of 
these seven variables had lower AIC values and were better at 
predicting survival compared to TNM staging. 
Conclusions: Models that take into consideration easily available 
epidemiological, clinical and key pathologic features may 
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provide a more precise prognostication of survival for patients 
with OCSCC compared to TNM staging. Further investigation of 
these prognostic roles is merited to allow individual patient risk-
stratification and may help in treatment decision and trial 
design. 
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Purpose: To compare outcomes among patients with localized 
esophageal and gastro-esophageal junction (GEJ) cancer who 
received concomitant chemo-radiation (CRT) using either 
cisplatin/5-FU or carboplatin/paclitaxel. CROSS 
trial demonstrated efficacy of carboplatin/paclitaxel in tri-
modality setting. However this regimen has also been 
adopted as an alternate for patients receiving CRT as 
definitive treatment due to better tolerance. 
Methods and Materials: Medical records of all patients diagnosed 
with localized carcinoma of esophagus and GEJ who underwent 
definitive CRT using cisplatin/5-FU, carboplatin/5-FU, or 
carboplatin/paclitaxel between January 2008 and March 2015 at 
our academic centre were reviewed. 
Results: Seventy-five patients (79% male) were identified with a 
median age of 74 years (range 45-86). Most (66%) had an 
adenocarcinoma and 37% squamous cell carcinoma. Sixty-three 
percent had distal 1/3rd and/or GEJ tumour. 48% received 
cisplatin/5-FU, 35% carboplatin/paclitaxel and 17% 
carboplatin/5-FU. Most patients (99%) received 50Gy in 25 
fractions. The median overall survival (OS) for cisplatin/5-FU 
group was 27 months (m) (95%CI 17-39) with three-year OS of 
42%, in contrast to 14 m (95%CI 11-17) and 13% among patients 
received carboplatin/paclitaxel (log-rank p = 0.006). The median 
OS for carboplatin/5-FU group was 17 m (95%CI 11-81) with 
three-year OS of 38%. Cisplatin/ 5-FU group had a significantly 
better distant metastasis free survival (median 20 versus 11 m, 
p = 0.04) when compared to carboplatin/paclitaxel group. On 
multivariate analysis, cisplatin/5-FU (hazard ratio(HR) 0.45, p = 
0.023) and carboplatin/5-FU group (HR 0.46, p = 0.093) were 
found to be associated with OS adjusted for other patient, 
disease and treatment related characteristics. 
Conclusions: We report that patients receiving cisplatin/5-FU 
had a significant survival benefit compared to patients who 
received carboplatin/paclitaxel as a definitive treatment for 
esophageal and GEJ cancer. Carboplatin/ 5FU might be a 
reasonable alternate for highly select patients. Clinical trials 
regarding optimal chemotherapy regimen are warranted for 
patients who are not surgical candidates. 
82 
PLANNED VERSUS ‘DELIVERED’ BLADDER DOSE RECONSTRUCTED 
USING SOLID AND HOLLOW ORGAN MODELS DURING PROSTATE 
CANCER IMRT  
Tara Rosewall1, Janelle Wheat2, Geoffrey Currie2, Vickie Kong1, 
Andrew Bayley1, Joanne Moseley1, Peter Chung1, Charles 
Catton1, Tim Craig1, Michael Milosevic1 
1Princess Margaret Cancer Centre, Toronto, ON 
2Charles Sturt University, Wagga Wagga, New South Wales, 
Australia 
Purpose: All studies to date have evaluated the dosimetric effect 
of bladder deformation using an organ model that includes the 
dose to the urine. This research reconstructed bladder dose using 
both hollow and solid organ models, to determine if dose/volume 
differences exist. 
Methods and Materials: Thirty-five prostate IMRT patients were 
selected, who had received 78 Gy in 39 fractions and full bladder 
instructions. Biomechanical modeling and finite element analysis 
was used to reconstruct bladder dose (solid and hollow organ 
model) using every third CBCT throughout the treatment course. 
Results: Reconstructed bladder dose was 11.3 Gy greater than 
the planned dose with a hollow model (p < 0.001) and 12.3Gy 
greater with a solid model (p < 0.0001). Median reconstructed 
volumes within the 30 Gy, 65 Gy and 78 Gy isodoses were 3-4 
times larger with the solid bladder model (p < 0.0001). Using a 
solid bladder model resulted in a difference between planned 
and reconstructed dose that was 10% larger than when using a 
hollow model. The difference between planning bladder volume 
and median treatment volume was associated with the 
difference between the planned and reconstructed dose below 
78 Gy (R2 > 0.61). 
Conclusions: Substantial differences exist between planned and 
reconstructed bladder dose, associated with the differences in 
bladder filling between planning and treatment. Dose 
reconstructed using a solid bladder model over-reports the 
volume of bladder within key isodose levels and overestimates 
the differences between planned and reconstructed dose. Dose 
reconstruction with a hollow organ model is recommended if the 
goal is to associate that dose with toxicity. 
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Purpose: Follicular lymphoma (FL) is a progressive relapsing 
hematologic malignancy. At The Ottawa Hospital (TOH), 
autologous hematopoietic cell transplantation (AHCT) utilizing 
total body irradiation (TBI) has been used to treat relapsed FL 
patients for over 20 years. We reviewed our large single 
institution experience and assessed outcomes and late toxicity. 
Methods and Materials: We retrospectively reviewed 
consecutive patients undergoing AHCT for relapsed FL from July 
1991 to February 2013. The pre-AHCT conditioning regimen was 
commonly Etoposide/Melphalan/TBI. Patients received TBI on a 
linear accelerator using a translating-bed technique. The total 
dose was 5 Gy/1fr for 92% of patients, the remainder received 
12Gy/6fr. Lung attenuators were used to maintain dose 
homogeneity. Patient information was stored on our bone 
marrow transplant (BMT) database. Descriptive statistics were 
calculated for all relevant demographic variables. Overall 
survival was estimated from the BMT date using the Kaplan-Meier 
method. Second malignancies were reported. Late toxicity was 
assessed in patients with at least one year of follow up (FU). 
Lung, kidney and thyroid toxicity was evaluated through 
extensive chart reviews. Clinical toxicity, creatinine, PFTs, chest 
imaging, thyroid function tests were assessed pre-AHCT and 
post-AHCT. 
Results: We evaluated 174 patients with a median age of 50 years 
at transplant. There were 106 men and 68 women. Median follow 
up was 6.0 years. Median follow up among survivors was 8.3 
years. Overall survival at one, five, 10 and 15 years was 93%, 
73%, 57% and 47% respectively. Eighteen patients (10.3 %) 
developed a second malignancy; 11 (6.3%) had solid tumours, two 
(1.1%) had AML and five (2.9%) developed myelodysplastic 
syndrome. Median time to second malignancy was 7.2 years, with 
cumulative incidences of developing second cancer at 5% and 8% 
at five and 10 years. We evaluated 149 patients with at least one 
year of follow up. Of 80 assessable patients, 23% developed 
hypothyroidism; 3% were hypothyroid beforehand. Pre-AHCT, 
creatinine ranged from 41 to 139 umol/L. Post AHCT, at last FU, 
of 116 patients, creatinine (umol/L) was < 100 in 63%, 100-150 
in 20%, 151-200 in 6% and > 200 in 9%. Hemodialysis was required 
for two patients. Clinical lung toxicity was noted in 6% of 95 
patients. PFTs were recorded in 26 patients pre-AHCT and 46 
patients post-AHCT. Abnormalities in DLCO were noted in 17% 
pre-AHCT and 26% of post-AHCT. Abnormalities in FEV1 were 
noted in 11% pre-AHCT and 25% of post-AHCT. Radiologic 
abnormalities were noted in 39%, with 23% being fibrotic 
changes, possibly radiation-induced, and 17% likely unrelated. 
Conclusions: Our results with TBI-based AHCT for relapsed FL are 
very good, with most patients surviving 10 years post-AHCT. 
